• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes.

作者信息

Marx Nikolaus

机构信息

Department of Internal Medicine II - Cardiology, University of Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany.

出版信息

Diab Vasc Dis Res. 2008 Nov;5(4):345-6. doi: 10.3132/dvdr.2008.048.

DOI:10.3132/dvdr.2008.048
PMID:18958845
Abstract
摘要

相似文献

1
PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes.PERISCOPE研究以及吡格列酮对糖尿病患者冠状动脉疾病进展的影响。
Diab Vasc Dis Res. 2008 Nov;5(4):345-6. doi: 10.3132/dvdr.2008.048.
2
PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.展望：吡格列酮具有一系列恰当的效应，能为2型糖尿病患者带来益处。
Cardiovasc J Afr. 2008 May-Jun;19(3):159-62.
3
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.降低三酰甘油/高密度脂蛋白胆固醇比值与吡格列酮对糖尿病患者冠状动脉粥样硬化进展的有益影响有关：来自 PERISCOPE（吡格列酮对血管内超声冠状动脉阻塞消退的影响前瞻性评估）研究的见解。
J Am Coll Cardiol. 2011 Jan 11;57(2):153-9. doi: 10.1016/j.jacc.2010.06.055.
4
Seeking alternatives to Hard End Points: is imaging the best APPROACH?寻找硬终点的替代方案：影像学是最佳方法吗？
Circulation. 2010 Mar 16;121(10):1165-8. doi: 10.1161/CIR.0b013e3181d83b4f. Epub 2010 Mar 1.
5
Pioglitazone vs glimepiride in the PERISCOPE trial.在“展望”试验中吡格列酮与格列美脲的对比
JAMA. 2008 Aug 20;300(7):787-8; author reply 788. doi: 10.1001/jama.300.7.787-b.
6
Pioglitazone vs glimepiride in the PERISCOPE trial.在PERISCOPE试验中吡格列酮与格列美脲的比较
JAMA. 2008 Aug 20;300(7):787; author reply 788. doi: 10.1001/jama.300.7.787-a.
7
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.芝加哥、视野和积极行动：吡格列酮改善糖尿病患者的心血管风险。
Fundam Clin Pharmacol. 2009 Dec;23(6):675-9. doi: 10.1111/j.1472-8206.2009.00741.x. Epub 2009 Sep 10.
8
Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis.噻唑烷二酮类药物对裸金属支架靶血管血运重建的不同影响：一项荟萃分析。
Cardiovasc Revasc Med. 2010 Oct-Dec;11(4):227-31. doi: 10.1016/j.carrev.2009.06.001.
9
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".对关于文章《罗格列酮与糖尿病合并冠状动脉疾病患者在旁路血管成形术血运重建调查2糖尿病（BARI 2D）试验中的结局》的信件的回复
Circulation. 2014 Apr 22;129(16):e460-1. doi: 10.1161/CIRCULATIONAHA.113.008033.
10
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.吡格列酮与格列美脲对 2 型糖尿病患者冠状动脉钙进展的影响：CHICAGO 研究的次要终点。
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1873-6. doi: 10.1161/ATVBAHA.110.207696. Epub 2010 Jun 24.

引用本文的文献

1
Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells.过氧化物酶体增殖物激活受体-γ 激动剂可预防同种反应性 T 细胞诱导的人动脉体内重构。
Circulation. 2011 Jul 12;124(2):196-205. doi: 10.1161/CIRCULATIONAHA.110.015396. Epub 2011 Jun 20.